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A better understanding of the mechanisms underlying radio-
responsiveness could help predict which patients are most likely to
benefit from radiotherapy, and also holds the possibility of selec-
tively modulating these mechanisms to improve the radio-
curability of human cancer. Human in vitro cell lines of different
histological origins which exhibit a range of intrinsic radiosensi-
tivity, as measured by clonogenic cell survival assays, have been
shown to provide appropriate models of the response of clinical
tumours to radiotherapy (Fertil and Malaise, 1981; Deacon et al,
1984). We are therefore attempting to identify those genes whose
protein expression is related to intrinsic radiosensitivity in a wide
range of human in vitro cell lines. Such gene expression should
prove to be relevant with regard to clinical radioresponsiveness.
The molecular basis of intrinsic radiosensitivity has been
investigated for many years. A considerable body of research has
focused on the degree of DNA damage and its subsequent repair as
reflected in the incidence of double-strand breaks (dsbs) in the
DNA (Kelland et al, 1988; Schwartz et al, 1991), the residual
damage remaining in the DNA after cellular rejoining of dsbs
(Nunez et al, 1995; Whitaker et al, 1995) and the fidelity of DNA
repair (Powell and McMillan, 1994). In addition to DNA damage,
however, it has become increasingly apparent that certain onco-
genes and tumour suppressor genes may not only be implicated in
carcinogenesis, but can also influence the sensitivity of malignant
cells to ionizing radiation.
Transfection of normal cell lines with dominant oncogenes such
as myc and ras (McKenna et al, 1990) has resulted in increased
radioresistance, even in the absence of detectable changes in the
rate of dsb induction (Iliakis et al, 1990). Several other dominant
oncogenes including c-fms, v-sis, v-erb-B, v-abl, v-src, v-cot
(FitzGerald et al, 1990; Shimm et al, 1992; Suzuki et al, 1992) and
in particular c-raf-1 (Kasid et al, 1987; 1989; Pirollo et al, 1989),
have also been reported to modulate cellular radiosensitivity in
mammalian cells. The potential relevance of these findings to
clinical radiotherapy has been emphasized by our own observation
that, in contrast to the c-raf-1 activated oncogene (Kasid et al,
1989), high levels of the normal protein product of the RAF1
proto-oncogene are positively related to intrinsic radiosensitivity
in human in vitro cell lines (Warenius et al, 1994). An additional
body of evidence indicates a positive relationship between muta-
tion in the p53 tumour suppressor gene and increased cellular
radioresistance in both rodent and human tumour cells (Lee and
Bernstein, 1993; Fan et al, 1994; Radford, 1994; Xia et al, 1995;
Zhen et al, 1995) and in normal cells transfected with mutant 
p53 (mutp53) genes (Bristow et al, 1994; Pardo et al, 1994;
Kawashima et al, 1995).
A number of reports suggest that oncogenes and tumour
suppressor genes may modulate intrinsic radiosensitivity by their
influence on the progress of irradiated cells through radiation-
induced blocks at cell-cycle checkpoints. G1/S delay, mediated
by p53 following exposure to ionizing radiation, has been impli-
cated as an important measure of cell-cycle perturbation which
correlates with relative radiation sensitivity (Kastan et al, 1991;
McIlwrath et al, 1994; Siles, 1996). Also, the expression of domi-
nant oncogenes such as myc and ras (McKenna et al, 1991) or
SV40 T antigen (Su and Little, 1993) has been shown to induce
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delay at the G2/M checkpoint. We have previously demonstrated
that radiosensitive human cancer cells, with high as opposed to
low expression of the normal RAF1 protein, exhibit more rapid
exit from a G2/M block induced by 2 Gy of radiation than
radioresistant cells with low expression of RAF1 (Warenius et al,
1996).
Most studies up to the present have concentrated on the
individual roles of oncogenes and tumour suppressor genes in
modulating intrinsic radiosensitivity. When investigating the
relationship between expression of a chosen gene and intrinsic
radiosensitivity, consideration has not necessarily been given as to
whether other candidate genes than the one selected for study
might also have an affect on the outcome of experiments. This
consideration could be particularly relevant in human clinical
cancers, the majority of which exhibit multiple disorders of
expression of oncogenes and suppressor genes. Moreover, little is
known about whether, or how, human oncogenes and suppressor
genes may interact to influence the radiosensitivity of cancer cells
in the clinical situation. However, transfection experiments using
cells from other mammals, such as rat embryo fibroblasts (REF),
have demonstrated greater increases in radioresistance in cells
expressing dominant plus cooperating oncogenes than expressing
the single dominant oncogenes alone (McKenna et al, 1990;
Pirollo et al, 1993; Su and Little, 1993). Similarly, radioresistance
induced in REF cells by transfection with multiple-integrated
mutant p53-pro193 alleles was much greater when the mutant p53
gene was co-transfected with H-ras (Bristow et al, 1994). In the
human in vitro cell lines which we are using as a model system,
there is considerable disorder of gene expression, and there is no
clear relationship between the patterns of protein expression of
different oncogenes or proto-oncogenes. We have therefore not
been able to investigate the putative influence of co-expression of
oncogenes on intrinsic radiosensitivity at the protein level. In order
to progress to a better understanding of the influence of multiple
genes on radiosensitivity and the possible interaction of proto-
oncogenes and suppressor genes, we have, therefore, investigated
the effect of the mutational status of the p53 gene on our previ-
ously-described relationship between RAF1 protein, radio-
sensitivity and exit from a radiation induced G2/M cell-cycle
checkpoint block.
MATERIALS AND METHODS
Cell lines and clonogenic cell survival assays
The growth characteristics, irradiation and clonogenic assay
procedures and radiation cell survival of the 12 human in vitro cell
lines in which the p53 mutational status has now been determined,
have already been reported (Warenius et al, 1994). The cell lines
are listed, with their histological classification in Table 1. All are
well established, many having been growing in vitro for several
years. Cell lines were either donations or purchased by our labora-
tories. On receipt all were grown for five passages to provide suffi-
cient cells for batch storage in liquid nitrogen. During this period,
contamination was excluded by at least one passage in antibiotic-
free medium, and mycoplasma testing was carried out on all lines.
For clonogenic assays, cells were taken from a designated primary
liquid nitrogen batch and grown for 3–6 passages until there were
sufficient well-growing cells. Further batches from these cells
were frozen in liquid nitrogen. Cells were routinely maintained in
DMEM medium except RT112 and H322, which were grown in
RPMI1640 and MGHU-1 which were grown in Ham’s F12
medium. All lines were supplemented with 10% heat-inactivated
fetal calf serum (HIFCS).
As previously described (Warenius et al, 1994; 1996), the
radiosensitivity of the 12 human lines described here was obtained
from radiation cell survival curves consisting for the majority of
cell lines of 6–12 dose points over the range 0–6 Gy and then at 1
Gy intervals to 8–10 Gy, as appropriate. For each cell line repeated
assays were performed until sufficient data were obtained to give
statistically acceptable values for α (the initial slope of the radia-
tion cell survival curve) and β when fitted by the linear quadratic
equation (below). Following irradiation from a 4 MeV linear
accelerator, at 2 Gy min–1 or a 137Cs Gammacell unit at 4 Gy min–1,
exponentially growing cells were seeded at densities from 102 to 
5 × 104 in 5 ml of Ham’s F12 medium plus 10% FCS in 60 mm
petri dishes and incubated at 37° C in 5% CO2 for 10–14 days. The
cells were then fixed in 70% ethanol, stained with 10% Giemsa
and colonies of greater than 100 cells counted. Cell-survival
curves were obtained by fitting the experimental data points with
the linear quadratic equation:
S = e– (α D+β D2)
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Table 1 Mutations detected in the p53 gene and consequent amino-acid changes in 7/12 human cell lines
Cell linea Source cDNA sequenceb Amino-acid change p53 proteinc
1407 Embryonic intest. epith. Normal none Wild-type
HEP 2 Squamous carcin. larynx Normal none Wild-type
MGHU 1 Transit. carcinoma bladder Normal none Wild-type
HRT18 Adenocarcinoma rectum Normal none Wild-type
2780 Ovarian carcinoma Normal none Wild-type
OAW 42 Ovarian carcinoma CGA–CGG codon 213 none Wild-type
HT 29/5 Adenocarcinoma colon CGT–CAT codon 273 Arg–His Mutant
COLO 320 Adenocarcinoma colon CGG–TGG codon 245 Arg–Tryp Mutant
H 322 Small cell carcinoma lung CGG–TGG codon 245 Arg–Tryp Mutant
H 417 Small cell carcinoma lung GAG–TAG codon 298 Glu–Stop Truncated
RPMI 7951 Melanoma TCA–TTA codon 166 Ser–Stop Truncated
RT 112 Transit. carcinoma bladder CCG–CAG codon 248 Arg–Gly Mutant
a Origin and growth conditions described in Materials and Methods; b Sequencing was carried out by the dideoxynucleotide enzymatic method
using the fmol DNA Sequencing System, as described in Materials and Methods; c As predicted by cDNA sequence1086 HM Warenius et al
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where S is the surviving fraction at dose D and α and  β are
constants. The data were fitted to the equation using a Graphpad
Prism program (GraphPad Software, San Diego, CA, USA). SF2
values (the surviving fraction at 2 Gy) were obtained by interpola-
tion of the fitted cell-survival curves.
Identification of mutations in the p53 gene by PCR and
DNA sequencing
Material for PCR and DNA sequencing of p53 and Western blot-
ting for RAF1 protein, was obtained from the same liquid nitrogen
batches used to provide cells for clonogenic cell-survival data.
Cells were grown for up to three passages prior to being subjected
to the following procedures.
Nucleic acid isolation
RNA and genomic DNA were prepared from the cell lines
described here by the guanidinium isothiocyanate CsCl gradient
method (Chirgwin et al, 1979; Barraclough et al, 1987). Briefly,
the cells were collected in ice-cold phosphate-buffered saline
(PBS) and homogenized in guanidinium isothiocyanate buffer (4M
guanidinium isothiocyanate, 50 mM Tris pH 7.5, 25 mM EDTA
pH 8.0, 0.5% (w/v) sodium lauryl sarcosine and 8% (v/v) 2-
mercaptoethanol) added just prior to use. The homogenate was
cleared by centrifugation at 8000 rpm for 10 min at 4° C (SS34
rotor, Sorvall RC-5B centrifuge) and the RNA pelleted by
centrifugation of the homogenate through a cushion of 5.7 M CsCl
0.1 M EDTA at 32 000 rpm for 20 h at 20° C (TST 41.14 rotor,
Kontron Centrikon T20 60 ultracentrifuge). The pellet of RNA
was redissolved in 0.1% (w/v) SDS and precipitated with ethanol
overnight at –20° C before quantitation.
Polymerase chain reaction, cDNA synthesis and nucleotide
sequencing
PCR (for exons 2–8 and for exons 9–11) was performed on DNA
and RNA extracted from the 12 human carcinoma cell lines. Each
exon was then examined by DNA sequencing. PCR primers were
designed flanking each exon and synthesized on an Applied
Biosystems 381A DNA synthesizer. Each exon was amplified
separately with the exceptions of exons 2 and 3 which were
amplified as a unit, and exons 9, 10 and 11 which were amplified
together by reverse transcription polymerase chain reaction (RT-
PCR). The following primers were used:
Exon 2/3 sense 5′ -CCC ACT TTT CCT CTT GCA GC-3′
Exon 2/3 antisense 5′ -AGC CCA ACC CTT GTC CTT AC-3′
Exon 4 sense 5′ -CTG CTC TTT TCA CCC ATC TA-3′
Exon 4 antisense 5′ -GCA TTG AAG TCT CAT GGA AG-3′
Exon 5 sense 5′ -TGT TCA CTT GTG CCC TGA CT-3′
Exon 5 antisense 5′ -CAG CCC TGT CGT CTC TCC AG-3′
Exon 6 sense 5′ -GCC TCT GAT TCC TCA CTG AT-3′
Exon 6 antisense 5′ -TTA ACC CCT CCT CCC AGA GA-3′
Exon 7 sense 5′ -ACT GGC CTC ATC TTG GGC CT-3′
Exon 7 antisense 5′ -TGT GCA GGG TGG CAA GTG GC-3′
Exon 8 sense 5′ -T ATC CTG AGT AGT GG-3′
Exon 8 antisense 5′ -T GCT TGC TTA CCT CG-3′
Exon 9/10/11 sense 5′ -AGA AAG GGG AGC CTC ACC AC-3′
Exon 9/10/11 antisense 5′ -CTG ACG CAC ACC TAT TGC
AA-3′
Genomic DNA was digested with EcoR1, precipitated with
ethanol and resuspended in 50 µ l of water (Sigma) before being
subjected to PCR amplification. The DNA (1 µ g) was amplified in
50 µ l PCR reactions containing 20 pmoles of each primer. A ‘hot-
start’ PCR protocol was used with the dNTPs and Taq enzyme
initially separated from the rest of the reaction components on a
wax cushion. The reactions were placed in a pre-heated PCR block
at 95° C for 2 min before undergoing 30 cycles of denaturation 
(30 s at 95° C), annealing (30 s at 60° C for exons 2–3, 4 and 6;
65° C for exons 5 and 8; 67° C for exon 7; and 68° C for exon 9–11)
and extension (1 min at 72° C). The PCR products were checked on
a 0.8% (w/v) agarose gel before being purified using a Wizard
minicolumn (Promega), and used directly in sequencing reactions.
cDNA synthesis and RT-PCR
Complementary DNA was synthesized from approximately 5 µ g
of total RNA using oligo(dT) as a primer. Total RNA (5 µ g),
human placental ribonuclease inhibitor (HPRI) 20 U and 1 µ g
oligo (dT) were heated at 70° C for 10 min, chilled on ice, added to
1 × first-strand buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl and
3 mM MgCl), 0.01 M DTT, dNTPs (0.5 µ M for each deoxyribo-
nucleoside triphosphate), 400 U of superscript reverse transcrip-
tase (Gibco) and incubated at 37° C for 1 h. PCR for exons 9–11
was carried out using 5 µ l of the above incubation in a 50 µ l of
PCR reaction, as described in the previous section.
Nucleotide sequencing
Sequencing primers (10 pmoles) were radioactively labelled at
their 5′ ends with γ 32P-ATP (45 µ Ci) at 37° C for 30 min in 
a reaction containing T4 polynucleotide kinase (PNK) (9.7 U,
Pharmacia) and 1 × T4 PNK buffer (10 µ M Tris-acetate, 10 µ M
magnesium acetate and 50 µ M potassium acetate). The primers
used were identical to those employed in the PCR reactions except
for exon 5, for which a separate sense sequencing primer was
designed as follows: 5′ -TAC TCC CCT GCC CTC-3′ . Sequencing
was carried out by the dideoxynucleotide enzymatic method
(Sanger et al, 1997), using the fmol DNA Sequencing System
(Promega). Any putative sequence mutations identified were
confirmed by additional sequencing of the exon in the antisense
direction as well as by carrying out a repeat PCR and sequencing
of the cell line.
Western blotting for RAF1
Two independent Western blottings with lysates for each cell line,
loaded in pairs on each gel, were carried out. 107 cells were grown
in 162 cm2 tissue culture flasks (Costar Ltd, High Wycombe, UK)
until they were pre-confluent and still growing exponentially.
Cells were then removed by trypsinization, resuspended in
complete medium plus 10% FCS and washed three times by serial
centrifugation and resuspension in PBS without serum. 1–3 × 108
viable cells were then pelletted by centrifugation and resuspended
at 3 × 107 cells per ml of lysis buffer (× 1 stock solution: 10% (w/v)
SDS 10 ml, 0.5 M Tris, pH 6.8, glycerol 10 ml, double-distilled
water 62 ml; to 10 ml of stock solution were added 100 µ l of 
10 µ M leupeptin plus 10 µ l 100 µ M PMSF). Protein estimations
were performed and the final concentration of the lysates adjusted
to 300 µ g total cellular protein per 100 µ l of lysis buffer. To
measure RAF1 protein, 150 µ g of total cellular protein in 50 µ l of
lysate buffer was added per lane to a 7.5% Laemmli separating gel
and electrophoresis carried out at 16° C using 60 V over 16 h and a
constant current of 500 mA. Proteins were transferred to nitro-
cellulose at 22° C over 16 h using a semi-dry blotting apparatus
(Biorad, Richmond, CA, USA), the membrane incubated with theURP26S3 mouse monoclonal antibody to human RAF1 (kindly
donated by Dr Ulf Rapp) and then with rabbit anti-mouse conju-
gated antibodies (Dako, UK) at 1/1000 and developed in alkaline
phosphatase buffer containing Nitroblue Tetrazolium 75 mg ml–1
in 70% (v/v) DMF and 5-bromo-4-chloro-3-indoyl phosphate
(Sigma, Poole, Dorset, UK) (50 mg ml–1 in dimethylformamide).
Quantitation of the full length 72–74 kD RAF1 protein product of
the  RAF1 proto-oncogene was carried out by measurement of
optical density on a Shimadzu scanning densitometer with tung-
sten light and expressed as OD units per 150 µ g of total cellular
protein. Titration curves obtained by loading different amounts of
total cellular protein have previously shown that linear relation-
ships for optical density (OD) could be obtained over the range
found for RAF1 protein across the cell lines (Warenius et al, 1994;
Browning, 1996). In order to compare different levels of RAF1
protein between the cell lines, the mean OD value for all the lines
was calculated and the relative OD for RAF1 protein in each indi-
vidual cell line was normalized to the mean OD and multiplied by
an arbitrary value of 5.0.
Measurement of exit from radiation-induced G2/M arrest
(T50)
All experiments were carried out on asynchronous, exponentially
growing cultures. Progress through G2/M following the relatively
low radiation dose of 2 Gy was followed because we were inter-
ested in the relative effects of radiation compared to RAF1 levels
and cell-cycle checkpoint perturbation at clinically relevant doses
(Warenius et al, 1994; 1996). Cells were plated at a density of
1.5–2  × 105 cells in 25 cm2 flasks (Costar) in 8 ml of normal
medium on the day before irradiation. Aliquots of cells were plated
in pairs of flasks for each time-point. Once the cells had attached,
the flasks were completely filled with medium containing 10%
(v/v) FCS and 20 mM HEPES and incubated at 37° C overnight.
One of each pair of flasks was either sham-irradiated (control in
Figure 1) or exposed to 2 Gy of γ -radiation from a 137Cs gammacell
unit at 4 Gy min–1. Care was taken to minimize any fall in temper-
ature during this stage.
Flow cytometry
Following irradiation the flasks were returned to the incubator and
subsequently harvested by trypsinization at 2 h intervals, washed
once in PBS, fixed in 70% (v/v) ethanol and stored at 4° C. For
DNA content analysis, fixed cells were pelleted and washed once
by centrifugation followed by resuspension in PBS containing 
20 µ g ml–1 propidium iodide (PI) and 100 µ g ml–1 RNase A.
Samples were incubated for at least 30 min before being filtered
through a 41 µ m nylon filter (Spectrum, Texas, USA) and then
analysed on a Becton Dickinson FACS 420 flow cytometer using
488 nm illumination and a 620 nm long-pass filter. Collected list
mode data was analysed using the ModfFit cell-cycle analysis 
software (Verity, Maine, USA). This enabled the relative distri-
bution of cells in the G1, S and G2/M phases of the cell cycle to be
determined. Three experimental runs each recording 2 h time-
points for 24 h for both irradiated cells and sham-irradiated controls
were carried out for each cell line. Data were plotted and linear
regression analyses carried out using a Fig P programme and 
non-parametric analyses were performed with an Arcus package.
RESULTS
Mutations were found in mRNA expressed from the p53 gene in
seven of the 12 cell lines. The mutations identified in the cell lines
described here were in exons 5–8, which are known to contain the
majority of p53 mutations (Hollstein et al, 1991). All these muta-
tions have been previously described, apart from the nonsense
mutation identified in codon 166 of the RPMI7951 line. This along
with the G–T transversion in codon 298 of H417 did not lie within
the most highly conserved region of the p53 gene. In the OAW42
ovarian carcinoma cell line the single-base missense mutation
from CGA–CGG was silent, so that the mutant triplet still coded
for the same amino acid (Arg) as is present in wtp53 protein
(Figure 1A). A normal p53 protein was thus expressed in six of the
12 cell lines. The mRNA of the other six cell lines coded for
abnormal p53 protein (Table 1). RPMI7951 and H417 possessed
stop mutations resulting in 165 and 297 amino acid-truncated
proteins, respectively. COLO320 and H322 independently exhib-
ited a missense G–C to A–T mutation at the same site, resulting in
an amino-acid substitution from Arg to Tryp. RT112 and HT29/5
also had mutations coding for changes in Arg (to Gly and His,
respectively). COLO320, H322 and RT112 were homozygous for
p53 mutations. The other three mutant lines showed evidence of
retention of heterozygosity (as shown for H417 in Figure 1B).
HT29/5 and RPMI7951 both expressed small amounts of wtp53
mRNA although H417 expressed relatively high levels. 50% of
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Figure 1 Regions of p53 cDNA dideoxy sequencing gels showing point
mutations in (A) OAW42 human ovarian cancer and (B) H417 human small
cell lung cancer cell linesour lines contained the residue 72 polymorphism which has been
recently described as playing an important role in the development
of human papilloma-virus-associated cancer (Storey et al, 1998).
These were evenly distributed between wild-type and mutant p53
cell lines.
The percentage of cells in the G2 phase of the cell cycle was
measured by flow cytometry at serial 2 h time-points following
exposure to 2 Gy of γ -irradiation, as previously described
(Warenius et al, 1996). No differences in the quality of the DNA
histograms of PI-stained cells were distinguishable between wtp53
and mutp53 cells (Figure 2). Post-irradiation G2 delay in mutp53
cells occurred around the same time-points of 10–14 h and was
generally less marked than in wtp53 cells (Figure 3). Otherwise
radiation-induced G2 delay appeared to be little affected by p53
mutational status per se. In both the wtp53 and mutp53 groups of
cell lines, a range from slight to marked radiation-induced G2 delay
was observed. The degree of G2 delay induced by 2 Gy of ionizing
radiation was quantified as described previously (Warenius et al,
1996) by measuring the rate of exit from the G2 block (expressed as
T50 (Table 2)). Although the T50 values for mutp53 cell lines
exhibited a higher mean (3.88) and range (1.29–7.77) than the T50
values for wtp53 (mean 3.42, range 1.85–4.99), both sets of values
fully overlapped and no significant differences in T50 were
apparent between the two groups of cell lines.
The relationship between RAF1 protein levels, intrinsic radio-
sensitivity (SF2), and the rate of exit from a radiation-induced G2
block was examined for all 12 cell lines and then independently in
1088 HM Warenius et al
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Figure 2 Flow cytometric histograms of propidium iodide (PI)-labelled
human in vitro cancer cell lines 12 h after exposure to 2 Gy of ionizing
radiation. Ordinate fluorescent intensity. Abcissa cell number
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Figure 3 Percentages of cells in the G2/M phase of the cell cycle obtained
by analysis of serial PI histograms over a period of 24 h following exposure to
2 Gy of ionizing radiation. For each 2-h time-point, the value of the sham-
irradiated cells was subtracted from that of its irradiated counterpart and the
mean ± 1 SEM of a minimum of three consecutive experiments was
calculated (A) wtp53, (B) mutp53. Vertical dotted line is peak of G2 delay.
Horizontal dotted line indicates time for 50% of cells to exit from peak G2/M
delay (T50)the wtp53 and mutp53 cells. Typical Western blots for RAF1
protein and p53 protein in the twelve cell lines are shown in Figure
4 at 0 and 8 h after irradiation with 2 Gy. No obvious changes were
apparent in the Western blots in any of the cell lines as a result of
irradiation for p53 or RAF1. The ranges of RAF1 protein levels in
wtp53 cells and mutp53 cells overlapped (3.33–10.39 and
3.58–8.46, respectively, Table 2), though the highest RAF1 values
were seen in the wtp53 cell lines. While RAF1 protein levels were
strongly correlated with SF2 for all 12 cell lines (r = –0.77, P =
0.004, Figure 5), in keeping with previous observations (Warenius
et al, 1994; 1996), no overall correlation was found between the
rate of G2 exit (T50) and RAF1 level (r = –0.19, P = 0.55) or
between T50 and SF2 (r = –0.04, P = 0.91).
Comparison of the wtp53 cell lines to the mutp53 cell lines,
however, (Figure 6) indicated that the mutual correlation between
radiosensitivity, a short T50 and high RAF1 protein expression
was only found in wtp53 cells. A highly significant negative rela-
tionship between RAF1 protein levels and T50 in wtp53 cells (r =
–0.97, P = 0.002) (Figure 6C) which was not present in the six cell
lines bearing p53 mutations (r = 0.19, P = 0.72) (Figure 6F) was
observed. A strong negative correlation between RAF1 protein
and SF2 in wtp53 cells (r = –0.92, P = 0.01, Figure 6A) was also
found. There was a similar, though weak trend in mutp53 cells (r =
–0.46, P = 0.36, Figure 6D). In the six wtp53 cell lines there was a
significant positive correlation between SF2 and T50 (r = 0.84, 
P = 0.04, Figure 6B), whereas the mutp53 group of cell lines
showed a non-significant correlation in the opposite direction 
(r = –0.77, P = 0.08, Figure 6E). Although the p53 mutant cell
lines were in general more radioresistant, it was not possible to
separate radiosensitive from radioresistant cell lines on the basis of
p53 mutational status alone. This was because, as seen in Table 2,
the SF2 values for wtp53 cells (range 0.22–0.54) overlapped with
those of mutp53 cells (range 0.34–0.60).
In order to be confident of our results it is important that the
means by which we have measured G2 exit takes into account
factors that could impact upon the ability of the T50 values to
show a correlation with SF2, and therefore also with RAF1 in the
mutant cell lines. For example, the rate of delivery of cells to G2
and the possible non-movement of cells through the cell cycle due
to cell death could potentially affect G2 accumulation. For this
reason, we chose to examine only the rate of exit from G2/M as
this was least likely to be influenced by factors occurring earlier in
the cell cycle. We have noted, however, in several of the cell lines
presented here, that when visualized under time-lapse microscopy
there is negligible cell death prior to the first mitosis (unpublished
data). In addition, when sequential changes in the G1 and S-phase
populations of the 12 cell lines were examined, it could be seen
that there was no evidence of early post-radiation impairment of
G1/S transit in wtp53 or mp53 cells (Figure 7) which might have
Combined RAF1/wild-type p53 predicts 1089
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Table 2 RAF1 protein, radiosensitivity and post-irradiation G2 exit in (A) wtp53 and (B) mutp53 human cell lines
Cell linea RAF1 proteinb Intrinsic radiosensitivityc Post-irradiation G2 exitd
SF2 T50 (h)
Wtp53
I 407 3.33 ± 1.31 0.54 4.99
HEP 2 3.82 ± 0.65 0.65 4.07
MGHU 1 5.27 ± 0.67 0.61 3.70
HRT18 5.94 ± 0.38 0.41 3.33
2780 9.25 ± 1.16 0.30 2.59
OAW 42 10.39 ± 1.16 0.22 1.85
Mutp53
HT 29/5 0.65 ± 0.18 0.59 5.18
COLO 320 5.44 ± 0.90 0.34 7.77
H 322 3.58 ± 0.17 0.53 2.03
H 417 8.46 ± 1.03 0.48 5.55
RPMI 7951 4.20 ± 0.43 0.56 1.29
RT 112 5.04 ± 0.91 0.60 1.48
a Origin and growth conditions described in Materials and Methods; b Arbitrary OD units ± 1 SEM calculated as
described in Materials and Methods; c SF2 values obtained by interpolation of cell survival curves fitted by the linear
quadratic equation to experimental cell survival data as described in Materials and Methods; d T50 values obtained
from experimental data depicted in Figure 3 as described in Materials and Methods
Irrad.
p53
Cell Line
A
B
Control.
Irrad.
Raf 1
Control.
Colo320 2780 H322 H417 Hep 2 HT29.5 HRT18 I407 MGHU OAW RPMI RT112
Irrad.
p53
Cell Line
Control.
Irrad.
Raf 1
Control.
Colo320 2780 H322 H417 Hep 2 HT29.5 HRT18 I407 MGHU OAW RPMI RT112
Figure 4 Typical Western blots of 12 human cell lines (A) immediately and
(B) 8 h following 2 Gy of gamma irradiation.potentially given rise to a different rate of delivery of cells to G2 in
the mutant as compared to the wild-type p53 populations. In both
wtp53 and mutp53 cells the first post-radiation cell-cycle change
observed was a small accumulation of cells in S-phase, indicating
a block of S-phase exit into G2 (Figure 8). The S-phase block had
cleared by around 4 h prior to the peak accumulation of cells in
G2/M in both groups and was thus unlikely to influence the G2/M
exit T50 value. In order to be certain that the results presented here
were not influenced by different cell-cycle transit times in the
wtp53 and mutp53 populations, we compared the values for poten-
tial doubling times (Tpots) for each group. Wild-type p53 cells had
a mean Tpot of 20.47 (range 9.69–29.94) and mutant p53 cells had
a mean Tpot of 20.01 (range 15.33–32.01) indicating closely
similar cell-cycle transit times in the two groups of cells. In
addition, Tpots were compared to T50 values in each group of
cells. It can be seen that there were no significant correlations
between Tpots and T50s in either the mutant or wild-type p53 cells
(Figure 9).
Serial changes in p53 and RAF1 protein levels were measured
over the 24-h periods during which cell-cycle changes were
recorded by flow cytometry (Figure 10). In all cell lines p53 and
RAF1 changes tended to move together, but no patterns of change
consistent with changes in the cell cycle were seen for either
protein and there were no obvious differences between mutant and
wild-type p53 cells.
DISCUSSION
Here we show that the relationship we have previously identified
between RAF1 expression and relative radiosensitivity can be
clearly demonstrated in human cell lines which express mRNA
coding for wtp53 protein but is absent in mutp53 cell lines. The
mutations detected in 7/12 of the cell lines are generally typical of
p53 mutations previously reported in human cancers. Many
reports investigating the mutational status of the p53 gene have
concentrated on sequencing exons 5–9 as this region is known to
contain the majority of mutations (Hollstein et al, 1991). However,
published data covering a wide range of cancers has estimated that
up to 6% of p53 mutations can occur outside exons 5–9 (de
Fromentel and Soussi, 1992). In order to be certain that we were
accurately assigning our cell lines as p53 mutants or wild-type, we
therefore chose to sequence the whole of the coding sequence of
the gene (exons 2–11). The Arg 273 and Arg 248 mutations we
identified occur at two of the known mutational hotspots in human
cancer and are residues that interact directly with DNA. The codon
245 Arg mutation has been previously reported in colon and lung
carcinoma cell lines (Rodrigues et al, 1990; Takahashi et al, 1991).
The codon 213 silent mutation in the OAW42 cell line is the site of
a polymorphism found in approximately 3.5% of the population
(Carbone et al, 1991; Mazars et al, 1992). A silent point mutation
at this site has also been described in breast carcinomas and
osteosarcomas (McIntyre et al, 1994).
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Figure 5 Relationship between RAF1 protein levels, radiosensitivity (SF2)
and rate of exit from a G2/M block following 2 Gy of γ -radiation (T50) for all
12 human cell lines irrespective of p53 mutational status (data from Table 2)
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Figure 6 Comparison of relationships between RAF1, radiosensitivity and
rate of exit from a post-irradiation G2/M block in p53 wild-type (A, B, C) and
p53 mutant (D, E, F) cell lines (data from Table 2)The identification of a very significant correlation between
RAF1 and intrinsic radiosensitivity in wtp53 cells, which was
absent in mutp53 cells (Figure 5A and 5B), indicates the potential
importance of examining the expression of more than a single gene
when attempting to relate gene expression and radioresponsiveness
in human cancer cells with heterogenous genotypes. Considerable
heterogeneity of gene expression is widely acknowledged to be
present in human cancers in the clinical situation. The difficulty in
extrapolating from simple experimental systems to complex
human diseases has been emphasized by Tada et al (1998), who
have reported that p53 mutations in cerebral glioblastomas are
surprisingly strongly associated with radioresponsiveness rather
than resistance to radiation therapy. The disparity of conclusions in
clinicopathological studies which have attempted to correlate the
status of the p53 gene alone to clinical outcome following radio-
therapy (reviewed by Bristow et al, 1996) may reflect the lack of
knowledge of the contemporaneous expression of other radiosensi-
tivity-determining genes in the genetically heterogenous material
obtainable from patients undergoing treatment for cancer. In these
clinicopathological studies, radioresponsiveness was examined in
relation to p53 mutational status determined by DNA sequencing
or to the levels of p53 protein detected by immunocytochemistry.
We have carried out Western blotting for p53 protein in the 12
lines described here using the CM1 antibody (unpublished data).
Combined RAF1/wild-type p53 predicts 1091
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Figure 7 Percentage of cells in the G1 and S phases of the cell cycle over
24 h obtained by analysis of serial PI histograms after exposure to 2 Gy
gamma irradiation (at time 0). For each 2-h time-point the value of the sham-
irradiated cells was subtracted from that of its irradiated counterpart and the
mean ± 1 SEM of a minimum of three consecutive experiments was
calculated (A) wtp53 (B) mutp53
20
10
—10
—20
0
M
e
a
n
I
r
r
-
C
o
n
t
02468 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4
Time (Hours)
20
10
—10
—20
0
M
e
a
n
I
r
r
-
C
o
n
t
02468 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4
Time (Hours)
A
B
%S
G1
G2
%S
G1
G2
Figure 8 Composite data from Figures 3 and 7 to illustrate overall time
courses for each cell-cycle phase change in G1, S and G2/M after 2 Gy of γ -
irradiation. Each 2-h time-point is the mean of means ± 1 SEM for each of the
(A) six wild-type and (B) six mutant cell linesThe p53 protein was detectable in all cells except the RPMI 7951
melanoma where the epitope recognized by CM1 was absent in the
truncated protein. No relationship between the level of p53 protein
and intrinsic radiosensitivity was detected. This finding is not
unsurprising, as it would be expected that the functionality of the
p53 protein, rather than the cellular concentration, would be of
most importance in relation to the effect of p53 on radiosensitivity.
In the cell lines examined here, those cells which contained p53
mutations and thus produced dysfunctional p53 proteins were, in
general, relatively radioresistant with SF2 values of 0.34–0.6.
Several other factors apart from structural abnormalities in the p53
gene may, however, influence its function. The cellular response to
ionizing radiation may be dependent on transcriptional activation
of the p53 gene which has been observed to be impaired in
Fanconi anaemia (Rosselli et al, 1995) and ataxia telangiectasia
(Kastan et al, 1992; Khanna and Lavin, 1993). In addition, p53
function has been shown to be regulated by post-translational
factors including those modifying its stability (Midgley and Lane,
1997) or its phosphorylation status. Several proteins have been
demonstrated to be capable of phosphorylating p53. These include
MAP kinase (Milne et al, 1994), DNA-activated protein kinase
(Lees Miller et al, 1992), casein kinase II (Milne et al, 1992),
CDK1 (Bischoff et al, 1992) and CDK2, which transactivate as
well as phosphorylate the p53 protein (Segawa et al, 1993).
Recently it has been reported that phosphorylation of the ser15
residue within the N-terminal transactivating region of the p53
protein has been observed following exposure to ionizing radiation
(Siliciano et al, 1998). It is possible that functional changes in
wtp53 protein due to interactions with other molecules may
provide a mechanism for the modulation of sensitivity to anti-
cancer agents. A study of Blagoskonny et al (1995) indicates that
induction of p53 and p21WAF1 in MCF7 human breast cancer
cells by Taxol has been shown to be dependent on the expression
of c-RAF1. To our knowledge there is at present no information
regarding the modulation of radiosensitivity by the interaction 
of RAF1 and p53. However, activated RAF1 has been shown to
phosphorylate and transactivate mouse p53 in the N-terminal
transactivation domain, possibly on ser18, which is the equivalent
residue to ser15 in the human p53 protein (Jamal and Ziff, 1995).
Our results are not consistent with a similar mechanism oper-
ating in the cell lines examined here. This is because, although
time-course experiments following the fates of p53 and RAF1 by
Western blotting showed that, in several cell lines, the two
appeared to move together, there was no clear correlation between
these post-radiation protein changes and radiosensitivity or G2/M
exit. Moreover, p53 and RAF1 did not co-immunoprecipitate or
show any evidence of phosphorylation on Western blotting. It is
thus possible that the statistical relationship which we have shown
between RAF1 expression and p53 status may be explained by
other factors that do not involve a direct p53/RAF1 interaction,
possibly involving p21WAF1/CIP. The results that we have
observed here, however, indicate that further experiments are
required to determine what mechanism may operate in wtp53
human in vitro cell lines which make RAF1 protein levels such a
strong correlator with radiosensitivity and G2/M exit. We are at
present co-transfecting certain of the wtp53 cell lines with a
temperature-sensitive p53 mutant and both full-length and trun-
cated activated RAF1 kinase genes under inducible-promoter
control to investigate RAF1/wtp53 involvement in radiosensitivity
and G2/M checkpoint control under isogenic conditions.
Not only do the levels of RAF1 protein relate strongly to
intrinsic radiosensitivity in the wtp53 human cell lines examined
here, but also both intrinsic radiosensitivity and RAF1 correlate
with the rate of exit of wtp53 cells, but not mutp53 cells, from a
G2/M block induced by 2 Gy of ionizing radiation (Figures 5B,
5C, 5E and 5F). These mutual inter-relationships suggest the
possibility that RAF1 and wtp53 may be influencing intrinsic
cellular radiosensitivity by interacting, in some as yet unknown
way, at the G2/M cell-cycle checkpoint. Lovric and Moelling
(1996) have reported five- to six-fold increased activation of
RAF1 kinase activity in the mitotic phases of the cell cycle of a
range of cell lines. This was accompanied by hyperphosphoryla-
tion of serine/threonine residues in the carboxy terminus of the
RAF1 protein. They have suggested that activation of c-RAF1 at
the G2/M boundary might be involved in p53 regulation, thereby
providing a mechanism by which RAF1 influences cellular
radiosensitivity. The association between high levels of RAF1
protein, relative radiosensitivity and rapid G2 exit in wild-type p53
cells seen in Figure 5 is consistent with this hypothesis and also
with reports that transfection of wild-type p53 was able to induce
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Figure 10 Serial measurements of p53 and RAF1 protein levels by quantitative Western blotting over 24 h following 2 Gy of gamma irradiation. Each time-
point is the mean of three independent experiments ± 1 SEM (A) wtp53, (B) mutp53radiosensitivity in association with rapid exit from a radiation-
induced G2/M block in two independent experimental systems
(Guillouf et al, 1995; Schwartz et al, 1997). However, several
studies have described increased transit through the G2/M check-
point in association with loss of wild-type p53 function (Aloni-
Grinstein et al, 1995; Paules et al, 1995; Stewart et al, 1995). In
order to explain these apparent discrepancies concerning the
action of p53 at the G2/M checkpoint, Schwartz et al (1997) have
suggested that in some cases p53 may arrest passage of cells
through G2/M until DNA damage is repaired, while in other
situations p53 may facilitate repair of DNA damage and hasten
progress through G2/M. The net effect of these processes may
depend on the type of DNA damage, the level of p53 expression
and the type of cell under investigation (Schwartz et al, 1997). We
have sought to minimize these variables by investigating the rela-
tionships of RAF1, p53 mutational status, the G2/M checkpoint
and intrinsic radiosensitivity in a range of human in vitro cell lines
which potentially allow the identification of general patterns of
gene expression relevant to clinical therapeutic responsiveness
against a heterogenous genetic background similar to that encoun-
tered in the patient. In the cell lines described here, the rate of exit
from a G2/M block evoked by 2 Gy of γ -irradiation was not related
to p53 mutational status per se, nor was p53 expression or muta-
tional status a predictor of radiosensitivity. The high correlation
we have obtained between SF2 and the level of expression of the
protein product of the RAF1 proto-oncogene in wild-type p53
cells, however, could potentially provide a useful test for detecting
the radioresponsiveness of certain tumours at dose levels
commonly employed in the clinic.
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